Date Title
October 12, 2017
Realm Therapeutics - Holding(s) in Company
RNS Number : 4478T Realm Therapeutics PLC 12 October 2017   TR-1: S tandard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of
October 9, 2017
Realm Therapeutics - Result of General Meeting
RNS Number : 0768T Realm Therapeutics PLC 09 October 2017   Realm Therapeutics plc ("Realm Therapeutics", "Realm" or the "Company")   Result of General Meeting All Resolutions Passed   9 October 2017 - Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on
September 22, 2017
Realm Therapeutics - Interim Results
RNS Number : 4999R Realm Therapeutics PLC 22 September 2017   The 'Interim Financial Results and Clinical Development Update' announcement for Realm Therapeutics plc released last night, 21 September 2017 at 18:00, RNS number '4970R' has been re-released in the interest of market clarity.
September 22, 2017
Realm Therapeutics - Proposed Placing to raise £19.3 million
RNS Number : 5001R Realm Therapeutics PLC 22 September 2017   The 'Proposed Placing to raise £19.3 million ( $26 million ) and Notice of General Meeting' announcement for Realm Therapeutics plc released last night, 21 September 2017 at 18:01, RNS number '4972R' has been re-released in the interest
September 21, 2017
Realm Therapeutics - Proposed Placing to raise £19.3 million
RNS Number : 4972R Realm Therapeutics PLC 21 September 2017   THIS ANNOUNCEMENT IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR FROM THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE
September 21, 2017
Realm Therapeutics - Interim Results
RNS Number : 4970R Realm Therapeutics PLC 21 September 2017       Realm Therapeutics plc ("Realm Therapeutics", "Realm" or the "Company" and together with its subsidiaries, the "Group")   Interim Financial Results and Clinical Development Update   Strong Progress with Two Investigational New Drug
September 11, 2017
Realm Therapeutics - FDA Permits PR013 to Proceed to Phase II Trial
RNS Number : 2996Q Realm Therapeutics PLC 11 September 2017       Realm Therapeutics plc ("Realm Therapeutics", "Realm" or the "Company")   FDA Permits Realm Therapeutics' PR013 to Proceed to Phase II Clinical Trial for Allergic Conjunctivitis Trial expected to commence by end of year, top line
September 7, 2017
Realm Therapeutics - Conference Presentation
RNS Number : 0321Q Realm Therapeutics PLC 07 September 2017       Realm Therapeutics plc ("Realm Therapeutics", "Realm" or the "Company")   Realm Therapeutics to present at the Rodman & Renshaw 19th Annual Global Investment Conference   7 September 2017 - Realm Therapeutics plc (AIM: RLM), a
August 18, 2017
Realm Therapeutics - Block listing Interim Review
RNS Number : 0789O Realm Therapeutics PLC 18 August 2017   Realm Therapeutics plc Block Listing Interim Review   Pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies Realm Therapeutics plc makes the following update on its block listing:   Date:   18 August 2017   Name of
August 2, 2017
Realm Therapeutics - Submission of Investigational New Drug Application
RNS Number : 8208M Realm Therapeutics PLC 02 August 2017       Realm Therapeutics plc ("Realm Therapeutics", "Realm" or the "Company")   Realm Therapeutics Submits Investigational New Drug Application for PR013 for Allergic Conjunctivitis   Second IND submission for Company this year   2 August
Displaying 81 - 90 of 156

Search Investor Relations